Catalent

$80$125

The Company is a specialty and generic drug manufacturing company. It focuses on advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. The vast majority of Catalent, Inc.’s sales are generated in the United States, followed by Europe and the rest of the world. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities

Report ID:

UMHE21284

Published:

Jan-2022

Pages:

15

Industry:

HeadQuatered Country:

United States

Geography:

Clear
  Get a Free Sample
SKU: UMHE21284 Category:
Scope
Table of content
Companies Mentioned

Scope

“Overview of the company and its product offering
Detailed insight into its Strategy, Value, Product Portfolio, and Business Headquarter
Information on its recent developments including partnerships, acquisitions, collaborations, and expansions among others
Biography of top management”

You can also purchase parts of this report. Do you want to check out a section wise
price list?

“1.    Key Facts of the Company
2.    Company Mission
3.    Company Value
4.    Growth Strategy
5.    Key Products & Services Offered
6.    Infographic
7.    Company Timeline
8.    Executive Team
9.    SWOT Analysis
10. Company Revenue Split
11.    Key Financials
12. Recent Developments
12.1 Product Launches
12.2 Partnerships
12.3 Business Expansion and Investments
12.4 Merger and Acquisitions”

Companies Mentioned

“Acorda Therapeutics, Inc.
Johnson & Johnson
Janssen Pharmaceutical NV
Janssen Pharmaceuticals, Inc.
AvantiBio”